---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-103215"
form_type: "8-K"
ticker: "NKTR"
cik: "0000906709"
company_name: "NEKTAR THERAPEUTICS"
filed_at: "2026-09-25T11:00:23+00:00"
generated_at: "2026-10-12T13:17:45.742150+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Nektar wins $90M jury verdict against Eli Lilly in rezpegaldesleukin license dispute

## Summary
- Jury found Lilly breached the implied covenant of good faith and fair dealing in the rezpegaldesleukin license deal; verdict returned Sept 24, 2026 (N.D. Cal. 3:23-cv-03943-JD).
- Jury awarded Nektar $90 million in damages plus interest, with the interest amount to be determined by the District Court.
- Nektar filed the complaint in August 2023 alleging breach of contract and breach of implied covenant; jury trial began September 8, 2026.
- Verdict remains subject to post-trial proceedings and any resulting judgment may be subject to appeal.

## SEC filing metadata
- accession: 0001213900-26-103215
- form_type: 8-K
- ticker: NKTR
- cik: 0000906709
- company_name: NEKTAR THERAPEUTICS
- filed_at: 2026-09-25T11:00:23+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/906709/000121390026103215/0001213900-26-103215-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/906709/000121390026103215/ea0306370-8k_nektar.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-103215
- JSON: https://secwatch.observer/filing/0001213900-26-103215.json
- Plain text: https://secwatch.observer/filing/0001213900-26-103215.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.